Introduction: The optimal role for postoperative radiotherapy (PORT) for thymoma and thymic carcinoma remains controversial. We used the National Cancer Data Base to investigate the impact of PORT on overall survival (OS).
Introduction
The thymic epithelial tumors, thymoma and thymic carcinoma, represent the most frequent tumors of the anterior mediastinum, although they remain relatively rare overall. 1 Surgery stands as the primary therapeutic modality in the curative setting, as extent of resection has consistently been shown to be independently prognostic of improved survival. 2, 3 The intimate association of these tumors with critical mediastinal structures can make complete resection difficult, particularly for advanced-stage disease. 4, 5 As a result, there has been a longstanding interest in utilizing *Corresponding author.
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postoperative radiotherapy (PORT) to improve outcomes. However, the precise indications for PORT and its magnitude of benefit have been difficult to ascertain. [6] [7] [8] The low annual incidence of thymic tumors renders the execution of randomized trials challenging, leaving only limited, conflicting data regarding the utility of PORT.
Large registry data sets, such as the Surveillance Epidemiology and End Results (SEER) database, have proved useful for investigating clinical questions in thymic tumors and other rare diseases for which there are inadequate data to address relevant questions. Given a lack of prospective evidence, several investigators have previously utilized the SEER database and other national data sets to investigate the role of PORT for thymic epithelial tumors. [9] [10] [11] [12] [13] [14] [15] [16] [17] Although these studies have been fairly heterogeneous in their design, consistent themes have emerged. PORT appears beneficial for patients with advanced disease (Masaoka-Koga stage III-IV) 9 ,10 but of minimal utility for completely encapsulated tumors (Masaoka-Koga stage I), [13] [14] [15] and it remains controversial for Masaoka-Koga stage II disease. 15, 16 Improved outcomes with the addition of PORT have been more readily demonstrated for patients with aggressive thymic carcinoma, as opposed to for those with thymoma histologic subtypes. [18] [19] [20] [21] Many retrospective, large-database studies have been unable to control for important confounders, including surgical margin status, histologic subtype, and use of chemotherapy; these studies have called for future studies to incorporate the aforesaid variables to provide more robust analyses.
The National Cancer Data Base (NCDB), which was queried for this study, includes additional information on these important variables. As a large hospital-based registry representing more than two-thirds of all cancer cases in the United States, the NCDB draws from a substantial number of institutions nationwide, thereby increasing the number of cases available for analysis. In this largest reported series on PORT for thymic tumors, we utilize the NCDB, with its unprecedented body of critical patient-and disease-specific factors, to describe outcomes and prognostic factors that identify patients who may benefit from adjuvant radiotherapy.
Methods

Data Source and Patient Selection
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. It is a hospital-based registry that represents 70% of all cancer cases in the United States, drawing data from more than 1500 commission-accredited cancer programs. The data used in the study are derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used, or for the conclusions drawn from these data by the investigators. 22 Before the present analysis was begun, appropriate exemption was obtained from our institutional review board.
The analysis was restricted to adult patients (age 18 years) in whom thymoma or thymic carcinoma, defined as International Classification of Disease for Oncology, Third Edition (ICD-O-3), histologic codes for thymoma (8580-8585) and thymic carcinoma (8002, 8010, 8012, 8013, 8020, 8021, 8070-8072, 8074, 8140, 8240, 8243, 8246, 8586, 8588, and 8589) with corresponding topographic codes C37.9 (thymus) and C38.1 (anterior mediastinum), had been diagnosed. 23 All patients included in the analysis were recorded as having undergone an operation and had their disease diagnosed from 2004 to 2012. All included cases had known treatment-related variables with respect to surgery, chemotherapy, and radiotherapy delivery, with unknowns excluded from this analysis. Treatment data coded in the NCDB are limited to the first course of treatment, defined as all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. Cases for which radiation was coded as being delivered before surgery or intraoperatively were excluded. Cases in which death occurred within 1 month of diagnosis were omitted from analysis.
Patient Demographics and Treatment Variables
Potentially relevant patient and treatment characteristics were selected a priori. Retrievable data included age, race, sex, insurance status, median income, treatment facility type, distance to facility, Charlson-Deyo comorbidity score, year of diagnosis, surgical margin status, WHO histologic subtype, use of radiation, use of chemotherapy, and derived MasaokaKoga stage group. To facilitate clinical applicability of this report, cases within the database were categorized according to the Masaoka-Koga staging system for thymic epithelial tumors: stage I to IIA (invasive tumor confined to gland of origin or localized, NOS), stage IIB (adjacent connective tissue), stage III (adjacent organs/structures in mediastinum), and stage IV (further contiguous extension, lymph nodes, or metastasis). As neither the SEER database nor the NCDB codes for microscopic transcapsular invasion, stage I disease could not be distinguished from stage IIA disease. Median household income in the patient's home zip code was recorded in quartiles relative to the U.S. population. Distance to treatment facility was recorded as the distance in miles between the hospital that reported the case and the patient's zip code centroid or city if the zip code was not available. Patient comorbidities were categorized by comorbidity score as described by Charlson and Deyo (1992) , and cases were coded as 0, 1, or 2 or higher. 24 
Statistical Analyses
All statistical analyses were performed using SPSS, version 23.0 (SPSS, Inc., Chicago, IL). Median follow-up was calculated with the reverse Kaplan-Meier method described by Schemper and Smith. 25 Pearson chi-square tests were used to evaluate patient-and treatmentrelated factors between patients who did or did not receive PORT. The primary end point was overall survival (OS) which is defined in the NCDB as date of diagnosis to the date of death. OS estimates were generated by using the Kaplan-Meier method and comparisons were made by using the log-rank test. Univariate hazard estimates were generated with unadjusted Cox proportional hazards models. Multivariate analysis for OS were performed by using Cox models adjusted for all variables selected a priori: age, race, sex, insurance status, median income, treatment facility type, distance to facility, Charlson-Deyo comorbidity score, year of diagnosis, surgical margin status, WHO histologic subtype, use of radiation, use of chemotherapy, and derived Masaoka-Koga stage group.
To further account for confounding variables, we performed propensity score matching for patients treated with or without PORT, accounting for the same variables described in the preceding paragraph. The propensity score was calculated by using logistic regression to estimate the probability of receiving radiation. One-to-one propensity matching without replacement was performed by using the caliper match algorithm described by Coca-Perraillon, 26 with the caliper width set to 0.05 times the standard deviation of the logit of the propensity score. 27 These outcomes were assessed with a log-rank test, and the hazard ratio (HR) was determined by univariate Cox regression. The score calculation was blinded with respect to patient outcomes.
Results
Patient Characteristics
A total of 4056 patients with thymoma (n ¼ 3031) or thymic carcinoma (n ¼ 1025) who met predefined selection criteria were identified. Median follow-up was 57.2 months (range 1.08-129.15 months) for patients with thymoma and 59.5 months (range 1.15-130.23) for patients with thymic carcinoma. The median age for patients with thymoma was 60 years (range 18-90 and older) and that for patients with thymic carcinoma was 61 years (range 19-90 and older). Use of adjuvant radiotherapy was evenly split among the cohort, as 1444 patients with thymoma (47.6%) and 557 patients with thymic carcinoma (54.3%) received PORT. The interquartile range for time from surgery to the start of radiation for all patients was 41 to 77 days. The overwhelming majority of patients presented with localized disease, with a higher proportion of thymic carcinomas (17.5%) being Masaoka-Koga stage IV at diagnosis. Patient-and disease-specific characteristics for both patients with thymoma and thymic carcinoma as well as for the surgery-alone and PORT treatment groups are listed in Table 1 . Differences were identified between the PORT and surgery-alone groups, with a general preponderance of adverse risk factors among those receiving PORT. Disease factors associated with the use of PORT included positive margins and advanced stage. Demographic factors associated with receipt of PORT included private medical insurance and residence within 50 miles of the treating facility.
OS for Patients with Thymoma
On univariate analysis of the entire thymoma cohort, despite the predominance of adverse disease-specific factors in the PORT group, PORT was associated with improved OS (HR ¼ 0.80, 95% confidence interval [CI]: 0.67-0.96, p ¼ 0.015). This includes all patients with thymoma irrespective of margin status. Univariate survival analyses for all variables are displayed in Table 2 . Kaplan-Meier survival curves for stage-specific subgroups are displayed in the top row of Figure  (Fig. 1A-C) .
On multivariate analysis, PORT remained independently associated with improved OS (HR ¼ 0.72, 95% CI: 0.59-0.87, p ¼ 0.001). A high median income was also associated with improved OS. The analysis showed an overall trend toward better outcomes in the latter years of the study, which reached significance for the years 2010-2012. Variables independently associated with inferior OS on multivariate analysis include older age, increased comorbidity score, positive margins, advanced Masaoka-Koga stage (III-IV), and use of chemotherapy (Table 3) .
Propensity score-matched treatment groups (n ¼ 1015 per group) were well balanced for all patient-and treatment-related factors between the surgery-alone and PORT groups. For the propensity-matched thymoma cohort, OS in patients receiving PORT was superior to that in patients receiving an operation alone (HR ¼ 0.64, CI: 0.52-0.79, p < 0.001).
OS for Patients with Thymic Carcinoma
On univariate analysis of the entire thymic carcinoma cohort, PORT was associated with improved OS (HR ¼ 0.79, 95% CI: 0.64-0.97, p ¼ 0.025). Univariate survival analyses for all variables are displayed in Table 4 . Kaplan-Meier survival curves for stage-specific subgroups are displayed in the bottom row of Figure 1 ( Fig. 1D-F) . This includes all patients with thymic carcinoma irrespective of margin status.
On multivariate analysis, PORT remained independently associated with improved OS (HR ¼ 0.73, 95% CI: 0.58-0.91, p ¼ 0.006). Variables independently associated with inferior OS on multivariate analysis include older age, uninsured status, positive margins, and advanced Masaoka-Koga stage (Table 5) .
Propensity score-matched treatment groups (n ¼ 345 per group) were well balanced for all patient-and treatment-related factors between the surgery-alone and PORT groups. For the propensity-matched thymoma cohort, OS in patients receiving PORT was superior to that in patients receiving an operation alone (HR ¼ 0.73, 95% CI: 0.57-0.94, p ¼ 0.016).
Secondary and Subgroup Analyses
Subgroup analysis for patients with thymoma was performed to evaluate the impact of PORT by histologic subtype, Masaoka-Koga stage group, and surgical margin status, with the corresponding forest plots depicted in Figure 2 . Utilization of PORT was associated with significantly longer survival in patients with the following characteristics: histologic subtypes A and B, stage IIB or III disease, and positive margins.
To help exclude the possibility that positive margins were influencing the benefit of PORT among patients with stage IIB disease, an additional subset analysis was performed. This multivariate analysis evaluated the impact of PORT in a subgroup of patients with marginnegative stage IIB thymoma. PORT remained associated with improved OS in this subgroup of 406 patients (HR ¼ 0.52, 95% CI: 0.28-0.96, p ¼ 0.037).
Discussion
The optimal use of PORT for patients with thymic epithelial neoplasms is unclear, particularly for patients with Masaoka-Koga stage II disease. The 2016 National Comprehensive Cancer Network guidelines acknowledge this controversy and recommend that clinicians consider PORT for completely resected Masaoka-Koga stage II disease. 28 Understandably, there is little current evidence on which to base any strong recommendation for PORT in this setting, and several smaller series have indicated no benefit for PORT in patients with stage II disease. [29] [30] [31] Retrospective analyses of the Chinese Alliance for Research of Thymoma database have generally found PORT to improve OS for margin-negative patients with thymic carcinoma but not thymoma. 32, 33 Additionally, two previous SEER database studies lacking data on many important baseline covariates identified longer OS associated with PORT in stage III to IV disease but no corresponding improvement for patients with stage IIB disease. 10, 15 By contrast, our NCDB study presented here demonstrates a clear OS advantage for PORT in both stage IIB and stage III thymoma. This effect persisted on additional subgroup analysis excluding positive margins, indicating that stage IIB patients with completely resected thymomas benefit as well. A recent smaller NCDB analysis by Boothe et al. that was limited to stage II and III patients also demonstrated improved OS with PORT for patients with thymic epithelial neoplasms. 34 Although there were differences in these two modern NCDB analyses owing to cohort definition and study design, both studies indicate a particular benefit of PORT for patients with positive margins and, to a lesser degree, for patients with WHO type A thymoma. Another recent, relatively well-powered study of 1263 patients from the International Thymic Malignancies Interest Group database also reported improved OS with PORT for patients with stage II and III thymoma. 35 Although overall their conclusions align well with data from the NCDB, they report an increased magnitude of benefit for PORT among those patients with WHO type B1, B2, and B3 disease, which conflicts with our data and that of other investigators using the NCDB. Future analyses from data sets with robust local control and causespecific death information are warranted to further clarify these conflicting observations. There are a few possible explanations as to why the present NCDB analysis indicates longer OS with PORT for stage IIB disease despite the fact that many previous series have been unable to demonstrate this finding. The present study analyzed 3031 thymoma cases (633 stage IIB), making it a very large series of a rare disease, which may provide sufficient power to see a survival advantage with improved local therapy. Previous studies have at times demonstrated favorable HRs for PORT but perhaps lacked the statistical power to detect a significant difference. Similar in size to the present analysis, a recent, well-powered meta-analysis by Zhou et al. also demonstrated improved OS for patients with stage II and III thymoma. 36 The NCDB also contains additional variables not available in the SEER database, such as margin status, consistent distinction of thymic carcinoma as a unique subtype, Charlson-Deyo comorbidity score, and chemotherapy use, which are all independently prognostic in the current study. Additionally, the time period analyzed may also help explain why longer OS with PORT was demonstrated in our modern NCDB analysis. Although previous studies have captured patients dating back as early as the 1970s, 9,10,15 our analysis is limited to 2004-2012, which is well within the era of advanced three-dimensional conformal radiotherapy and intensity-modulated radiation therapy. Conformal dose distributions made possible by high-quality modern radiotherapy techniques have the potential to decrease dose to critical nearby thoracic organs and may improve the therapeutic ratio of PORT. 37 Our inability to more specifically delineate Masaoka-Koga stage must be acknowledged as an important limitation of this analysis. Masaoka-Koga The present analysis has several other important limitations. This study is retrospective, nonrandomized, and therefore subject to selection bias or the influence of unknown variables that cannot be controlled for in the NCDB. In addition, data regarding specific chemotherapy drugs and dosing are lacking. Finally, OS is the only outcome measure reported; information regarding other important oncologic outcomes such as local control and progression-free survival are unavailable. Efforts to account for potential selection biases included the use of multivariate models and propensity score-matched analysis with well-balanced patient characteristics.
Conclusions
In this contemporary NCDB analysis, we present a large, contemporary evaluation of PORT for patients with thymoma or thymic carcinoma. A significant OS advantage was associated with PORT for patients with derived Masaoka-Koga stage IIB or stage III disease; no significant OS benefit was observed for patients with early-stage disease (I-IIA). Substantial benefits from PORT were also observed among patients with positive surgical margins, although patients with intermediateand advanced-stage thymoma with negative margins also appeared to benefit from PORT. In the absence of randomized data assessing the value of PORT, these data may inform clinical practice.
